Hypertrophied myocardium is vulnerable to ischemia/reperfusion injury and refractory to rapamycin-induced protection due to increased oxidative/nitrative stress.

Left ventricular hypertrophy (LVH) is causally related to increased morbidity and mortality following acute myocardial infarction (AMI) via still unknown mechanisms. Although rapamycin exerts cardioprotective effects against myocardial ischemia/reperfusion (MI/R) injury in normal animals, whether rapamycin-elicited cardioprotection is altered in the presence of LVH has yet to be determined. Pressure overload induced cardiac hypertrophied mice and sham-operated controls were exposed to AMI by coronary artery ligation, and treated with vehicle or rapamycin 10 min before reperfusion. Rapamycin produced marked cardioprotection in normal control mice, whereas pressure overload induced cardiac hypertrophied mice manifested enhanced myocardial injury, and was refractory to rapamycin-elicited cardioprotection evidenced by augmented infarct size, aggravated cardiomyocyte apoptosis, and worsening cardiac function. Rapamycin alleviated MI/R injury via ERK-dependent antioxidative pathways in normal mice, whereas cardiac hypertrophied mice manifested markedly exacerbated oxidative/nitrative stress after MI/R evidenced by the increased iNOS/gp91phox expression, superoxide production, total NO metabolites, and nitrotyrosine content. Moreover, scavenging superoxide or peroxynitrite by selective gp91phox assembly inhibitor gp91ds-tat or ONOO- scavenger EUK134 markedly ameliorated MI/R injury, as shown by reduced myocardial oxidative/nitrative stress, alleviated myocardial infarction, hindered cardiomyocyte apoptosis, and improved cardiac function in aortic-banded mice. However, no additional cardioprotective effects were achieved when we combined rapamycin and gp91ds-tat or EUK134 in ischemic/reperfused hearts with or without LVH. These results suggest that cardiac hypertrophy attenuated rapamycin-induced cardioprotection by increasing oxidative/nitrative stress and scavenging superoxide/peroxynitrite protects the hypertrophied heart from MI/R.

[1]  Anindita Das,et al.  Reperfusion Therapy with Rapamycin Attenuates Myocardial Infarction through Activation of AKT and ERK , 2017, Oxidative medicine and cellular longevity.

[2]  Yang Li,et al.  Hypercholesterolemia Abrogates Remote Ischemic Preconditioning-Induced Cardioprotection: Role of Reperfusion Injury Salvage Kinase Signals , 2017, Shock.

[3]  L. Køber,et al.  Left Ventricular Hypertrophy Is Associated With Increased Infarct Size and Decreased Myocardial Salvage in Patients With ST‐Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2017, Journal of the American Heart Association.

[4]  C. Drummond,et al.  Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling , 2016, Journal of the American Heart Association.

[5]  M. E. Shaker,et al.  The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. , 2016, Biochemical pharmacology.

[6]  D. Yellon,et al.  Ischaemic conditioning and reperfusion injury , 2016, Nature Reviews Cardiology.

[7]  T. Engstrøm,et al.  Increased myocardial vulnerability to ischemia–reperfusion injury in the presence of left ventricular hypertrophy , 2016, Journal of hypertension.

[8]  He Huang,et al.  SH2B1 is critical for the regulation of cardiac remodelling in response to pressure overload. , 2015, Cardiovascular research.

[9]  T. Matsui,et al.  Cardiac mTOR rescues the detrimental effects of diet-induced obesity in the heart after ischemia-reperfusion. , 2015, American journal of physiology. Heart and circulatory physiology.

[10]  Y. Liao,et al.  Pharmacological modulation of autophagy to protect cardiomyocytes according to the time windows of ischaemia/reperfusion , 2015, British journal of pharmacology.

[11]  R. Bolli,et al.  Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling , 2015, Basic Research in Cardiology.

[12]  Verena Albert,et al.  mTOR signaling in cellular and organismal energetics. , 2015, Current opinion in cell biology.

[13]  G. Heusch.  Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. , 2015, Circulation research.

[14]  M. Volpe,et al.  Mammalian target of rapamycin signaling in cardiac physiology and disease. , 2014, Circulation research.

[15]  Anindita Das,et al.  Mammalian Target of Rapamycin (mTOR) Inhibition with Rapamycin Improves Cardiac Function in Type 2 Diabetic Mice , 2013, The Journal of Biological Chemistry.

[16]  Mark A Sussman,et al.  Mechanistic Target of Rapamycin Complex 2 Protects the Heart From Ischemic Damage , 2013, Circulation.

[17]  Jianhua Zhang,et al.  Cellular metabolic and autophagic pathways: traffic control by redox signaling. , 2013, Free radical biology & medicine.

[18]  Mark A Sussman,et al.  mTORC2 Protects the Heart from Ischemic Damage , 2013 .

[19]  P. Pagliaro,et al.  Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. , 2013, Antioxidants & redox signaling.

[20]  Anindita Das,et al.  Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway. , 2012, Journal of molecular and cellular cardiology.

[21]  N. King,et al.  Propofol improves recovery of the isolated working hypertrophic heart from ischaemia–reperfusion , 2012, Pflügers Archiv - European Journal of Physiology.

[22]  I. Komuro,et al.  Association of Stat3 with HSF1 plays a critical role in G-CSF-induced cardio-protection against ischemia/reperfusion injury. , 2012, Journal of molecular and cellular cardiology.

[23]  Lei Zhao,et al.  Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1–53 attenuating myocardial oxidative stress injury induced by ischemia/reperfusion , 2012, Peptides.

[24]  W. Koch,et al.  Downregulation of adiponectin induced by tumor necrosis factor &agr; is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury* , 2011, Critical care medicine.

[25]  M. Hall,et al.  mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. , 2011, The Journal of clinical investigation.

[26]  T. Prolla,et al.  Mitochondrial Oxidative Stress Mediates Angiotensin II–Induced Cardiac Hypertrophy and G&agr;q Overexpression–Induced Heart Failure , 2011, Circulation research.

[27]  J. Rysä,et al.  Parthenolide inhibits STAT3 signaling and attenuates angiotensin II-induced left ventricular hypertrophy via modulation of fibroblast activity. , 2011, Journal of molecular and cellular cardiology.

[28]  K. Shimamoto,et al.  Hypertensive Hypertrophied Myocardium Is Vulnerable to Infarction and Refractory to Erythropoietin-Induced Protection , 2011, Hypertension.

[29]  S. Sollott,et al.  Role of Glycogen Synthase Kinase-3β in Cardioprotection , 2009, Circulation research.

[30]  Anthony J. Muslin,et al.  Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. , 2009, Kidney international.

[31]  Lei Xi,et al.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. , 2009, American journal of physiology. Heart and circulatory physiology.

[32]  Yajing Wang,et al.  INO-4885 [5,10,15,20-Tetra[N-(benzyl-4′-carboxylate)-2-pyridinium]-21H,23H-porphine Iron(III) Chloride], a Peroxynitrite Decomposition Catalyst, Protects the Heart against Reperfusion Injury in Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[33]  David A Bluemke,et al.  The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. , 2008, Journal of the American College of Cardiology.

[34]  S. Solomon,et al.  Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. , 2008, JACC. Cardiovascular imaging.

[35]  B. Vidne,et al.  The protective effect of prior ischemia reperfusion adenosine A1 or A3 receptor activation in the normal and hypertrophied heart. , 2007, Interactive cardiovascular and thoracic surgery.

[36]  Walter Koch,et al.  Adiponectin Cardioprotection After Myocardial Ischemia/Reperfusion Involves the Reduction of Oxidative/Nitrative Stress , 2007, Circulation.

[37]  A. Dart,et al.  Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis , 2006, Journal of hypertension.

[38]  G. Vetrovec,et al.  Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. , 2006, Journal of molecular and cellular cardiology.

[39]  A. Hsu,et al.  The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. , 2006, American journal of physiology. Heart and circulatory physiology.

[40]  W. Paulus,et al.  Peroxynitrite-induced alpha-actinin nitration and contractile alterations in isolated human myocardial cells. , 2005, Cardiovascular research.

[41]  M. Hall,et al.  The expanding TOR signaling network. , 2005, Current opinion in cell biology.

[42]  S. Izumo,et al.  Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload , 2004, Circulation.

[43]  W. Manning,et al.  Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice , 2003, Circulation.

[44]  Z. Xia,et al.  ERK1/2 Antagonizes Glycogen Synthase Kinase-3β-induced Apoptosis in Cortical Neurons* , 2002, The Journal of Biological Chemistry.

[45]  H. S. Klopfenstein,et al.  M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). , 2001, The American journal of cardiology.

[46]  E. Carluccio,et al.  Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction. , 2000, International journal of cardiology.

[47]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[48]  Haobo Li,et al.  Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans. , 2016, British journal of anaesthesia.